State Street Corp Salarius Pharmaceuticals, Inc. Transaction History

State Street Corp

  • $2.41 Trillion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
BUY
$1.02 - $1.52 $145,403 - $216,679
142,552 New
142,552 $151,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.37M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email